Early 2019 I contacted my PhD advisor Mike Carroll that I found PDL1 and PDL2 expressed on human FDC (JEM, 2021). Almost 7 years and a few CXCL13-Cre-PDL1-flox mice later we report in @cp-immunity.bsky.social what PDL1 does there! www.cell.com/immunity/abs...
Herculean effort by Elliot Akama-Garren!
Herculean effort by Elliot Akama-Garren!
PD-L1 expression in germinal centers promotes humoral immunity by restricting T follicular regulatory cell differentiation
PD-L1 is generally considered to suppress immune responses. However, Akama-Garren
et al. reveal an immunogenic role for PD-L1 in germinal centers. Expressed on B cell
zone reticular cells, including f...
www.cell.com
October 29, 2026 at 9:44 AM
Early 2019 I contacted my PhD advisor Mike Carroll that I found PDL1 and PDL2 expressed on human FDC (JEM, 2021). Almost 7 years and a few CXCL13-Cre-PDL1-flox mice later we report in @cp-immunity.bsky.social what PDL1 does there! www.cell.com/immunity/abs...
Herculean effort by Elliot Akama-Garren!
Herculean effort by Elliot Akama-Garren!
Online now: T cell cross-priming by PD-L1+ type 1 conventional dendritic cells mediates the antitumor efficacy of a PD-L1×4-1BB bispecific antibody
T cell cross-priming by PD-L1+ type 1 conventional dendritic cells mediates the antitumor efficacy of a PD-L1×4-1BB bispecific antibody
Bispecific PD-L1×4-1BB antibodies under clinical development enhance antitumor T cell responses. Luri-Rey et al. find that the efficacy of PD-L1×4-1BB antibodies relies on PD-L1-expressing type 1 conventional dendritic cells, which integrate antigen cross-presentation, IL-12, and 4-1BB costimulation to promote efficacious T cell-mediated antitumor immunity.
dlvr.it
October 28, 2026 at 7:55 PM
Online now: T cell cross-priming by PD-L1+ type 1 conventional dendritic cells mediates the antitumor efficacy of a PD-L1×4-1BB bispecific antibody
Isobavachalcone targets deubiquitinase OTUB1 to induce #PD-L1 degradation and enhances antitumor #immunity:
Cell Reports Medicine www.cell.com/cell-reports...
Cell Reports Medicine www.cell.com/cell-reports...
Isobavachalcone targets deubiquitinase OTUB1 to induce PD-L1 degradation and enhances antitumor immunity
Zhang et al. demonstrate that isobavachalcone targets the deubiquitinase OTUB1 to
promote PD-L1 ubiquitination and degradation in cancer cells. This regulation enhances
T cell-mediated antitumor immun...
www.cell.com
November 3, 2026 at 6:10 PM
Isobavachalcone targets deubiquitinase OTUB1 to induce #PD-L1 degradation and enhances antitumor #immunity:
Cell Reports Medicine www.cell.com/cell-reports...
Cell Reports Medicine www.cell.com/cell-reports...
📣 Pub Alert! 💡
This week, the following noteworthy scientific article was published, (co-)authored by scientists at NKI-AVL:
jnm.snmjournals.org/content/earl...
This week, the following noteworthy scientific article was published, (co-)authored by scientists at NKI-AVL:
jnm.snmjournals.org/content/earl...
18F-BMS-986192 PET to Predict Durable Response to Nivolumab in NSCLC: A Novel Approach Beyond PD-L1 Immunohistochemistry
Programmed death ligand 1 (PD-L1) immunohistochemistry, the current standard biomarker for predicting response to programmed death protein 1/PD-L1 checkpoint inhibitors in non–small cell lung cancer, ...
jnm.snmjournals.org
November 3, 2026 at 2:43 PM
📣 Pub Alert! 💡
This week, the following noteworthy scientific article was published, (co-)authored by scientists at NKI-AVL:
jnm.snmjournals.org/content/earl...
This week, the following noteworthy scientific article was published, (co-)authored by scientists at NKI-AVL:
jnm.snmjournals.org/content/earl...
Online now: PD-L1 expression in germinal centers promotes humoral immunity by restricting T follicular regulatory cell differentiation
PD-L1 expression in germinal centers promotes humoral immunity by restricting T follicular regulatory cell differentiation
PD-L1 is generally considered to suppress immune responses. However, Akama-Garren et al. reveal an immunogenic role for PD-L1 in germinal centers. Expressed on B cell zone reticular cells, including follicular dendritic cells, PD-L1 promotes humoral immunity by restraining a subset of T follicular helper cells that promotes T follicular regulatory cell development.
dlvr.it
October 28, 2026 at 2:48 PM
Online now: PD-L1 expression in germinal centers promotes humoral immunity by restricting T follicular regulatory cell differentiation
An extraction-free one-pot immunomagnetic-RPA-CRISPR/Cas13a platform for ultrasensitive detection of exosomal PD-L1 https://pubmed.ncbi.nlm.nih.gov/42967779/
November 2, 2026 at 10:41 AM
An extraction-free one-pot immunomagnetic-RPA-CRISPR/Cas13a platform for ultrasensitive detection of exosomal PD-L1 https://pubmed.ncbi.nlm.nih.gov/42967779/
Efficacy of PD-L1×4-1BB antibodies relies on PD-L1+ cDC1, which integrate antigen cross-presentation, IL-12, & 4-1BB costimulation to promote efficacious T cell-mediated antitumor immunity
www.cell.com/immunity/abs... @cp-immunity.bsky.social
www.cell.com/immunity/abs... @cp-immunity.bsky.social
October 29, 2026 at 12:07 AM
Efficacy of PD-L1×4-1BB antibodies relies on PD-L1+ cDC1, which integrate antigen cross-presentation, IL-12, & 4-1BB costimulation to promote efficacious T cell-mediated antitumor immunity
www.cell.com/immunity/abs... @cp-immunity.bsky.social
www.cell.com/immunity/abs... @cp-immunity.bsky.social
A division of labour for PD-1 ligands
A division of labour for PD-1 ligands
Nature Reviews Immunology, Published online: 03 November 2026; doi:10.1038/s41577-026-01372-5A preprint by Nah et al. reports that PD-L1 and PD-L2 on dendritic cells in the tumour versus tumour-draining lymph nodes have spatially regulated effects on the antitumour T cell response.
dlvr.it
November 3, 2026 at 1:09 PM
A division of labour for PD-1 ligands
PD-L1 on B cell zone reticular cells, including follicular dendritic cells, promotes humoral immunity by restraining a subset of Tfh that promotes Tfr development @cp-immunity.bsky.social @bostonchildrens.bsky.social
www.cell.com/immunity/abs...
www.cell.com/immunity/abs...
October 29, 2026 at 12:10 AM
PD-L1 on B cell zone reticular cells, including follicular dendritic cells, promotes humoral immunity by restraining a subset of Tfh that promotes Tfr development @cp-immunity.bsky.social @bostonchildrens.bsky.social
www.cell.com/immunity/abs...
www.cell.com/immunity/abs...
🔬 At #ESMO26, Laurence Albiges presented results on the reproducibility of PD-L1 status assessment in the pragmatic #CARE1 trial.
#KidneyCancer #RCC #PDL1 #ClinicalResearch #PragmaticTrials
#KidneyCancer #RCC #PDL1 #ClinicalResearch #PragmaticTrials
October 29, 2026 at 5:14 PM
🔬 At #ESMO26, Laurence Albiges presented results on the reproducibility of PD-L1 status assessment in the pragmatic #CARE1 trial.
#KidneyCancer #RCC #PDL1 #ClinicalResearch #PragmaticTrials
#KidneyCancer #RCC #PDL1 #ClinicalResearch #PragmaticTrials
#ESMO26: Phase III PERSEE #ClinicalTrial reports a 44% reduction in the risk of progression or death with the addition of #chemotherapy to pembrolizumab versus pembrolizumab alone in first-line advanced #NSCLC with #PD-L1 ≥50%
➡️ https://ow.ly/eWmC5100p3O
#InsightsbyESMO
Alfredo Addeo
➡️ https://ow.ly/eWmC5100p3O
#InsightsbyESMO
Alfredo Addeo
October 30, 2026 at 9:20 AM
#ESMO26: Phase III PERSEE #ClinicalTrial reports a 44% reduction in the risk of progression or death with the addition of #chemotherapy to pembrolizumab versus pembrolizumab alone in first-line advanced #NSCLC with #PD-L1 ≥50%
➡️ https://ow.ly/eWmC5100p3O
#InsightsbyESMO
Alfredo Addeo
➡️ https://ow.ly/eWmC5100p3O
#InsightsbyESMO
Alfredo Addeo
Worth noting for trainees: OptiTROP-Lung06 was in PD-L1-negative disease, the group where first-line immunotherapy has been least satisfying, which is why adding a TROP2 ADC there is such an interesting question.
November 2, 2026 at 6:33 PM
Worth noting for trainees: OptiTROP-Lung06 was in PD-L1-negative disease, the group where first-line immunotherapy has been least satisfying, which is why adding a TROP2 ADC there is such an interesting question.
The authors included RRIDs in their in Theranostics paper! RRIDs improve reproducibility in scientific research. #RRID #methodsmatter #OpenScience
Single-cell RNA sequence analysis reveals USP32 as a therapeutic target to mitigate PD-L1-driven colorectal tumorigenesis in vitro and in vivo
Read the full paper: Single-cell RNA sequence analysis reveals USP32 as a therapeutic target to mitigate PD-L1-driven colorectal tumorigenesis in vitro and in vivo
doi.org
November 1, 2026 at 7:00 AM
The authors included RRIDs in their in Theranostics paper! RRIDs improve reproducibility in scientific research. #RRID #methodsmatter #OpenScience
【PD-L1陽性頭頸部がん、死亡リスクが50％減った】
Genmabのペトセムタマブとペムブロリズマブの併用。第3相LiGeR-HN1で、ペムブロリズマブ単独に対し全生存期間と客観的奏効率の主要評価を達成。PD-L1陽性の再発・転移性頭頸部扁平上皮がんで、死亡リスクを50％低減。
Genmab、ペトセムタマブ併用療法の第3相試験で全生存期間を改善──PD-L1陽性頭頸部がん一次治療、死亡リスクを50％低減
stellanews.life/technology/1...
Genmabのペトセムタマブとペムブロリズマブの併用。第3相LiGeR-HN1で、ペムブロリズマブ単独に対し全生存期間と客観的奏効率の主要評価を達成。PD-L1陽性の再発・転移性頭頸部扁平上皮がんで、死亡リスクを50％低減。
Genmab、ペトセムタマブ併用療法の第3相試験で全生存期間を改善──PD-L1陽性頭頸部がん一次治療、死亡リスクを50％低減
stellanews.life/technology/1...
Genmab、ペトセムタマブ併用療法の第3相試験で全生存期間を改善──PD-L1陽性頭頸部がん一次治療、死亡リスクを50％低減
Genmabは、ペトセムタマブとペムブロリズマブの併用が、PD-L1陽性の再発・転移性頭頸部扁平上皮がんの一次治療で全生存期間と奏効率を有意に改善したと発表した。
stellanews.life
October 31, 2026 at 1:03 AM
【PD-L1陽性頭頸部がん、死亡リスクが50％減った】
Genmabのペトセムタマブとペムブロリズマブの併用。第3相LiGeR-HN1で、ペムブロリズマブ単独に対し全生存期間と客観的奏効率の主要評価を達成。PD-L1陽性の再発・転移性頭頸部扁平上皮がんで、死亡リスクを50％低減。
Genmab、ペトセムタマブ併用療法の第3相試験で全生存期間を改善──PD-L1陽性頭頸部がん一次治療、死亡リスクを50％低減
stellanews.life/technology/1...
Genmabのペトセムタマブとペムブロリズマブの併用。第3相LiGeR-HN1で、ペムブロリズマブ単独に対し全生存期間と客観的奏効率の主要評価を達成。PD-L1陽性の再発・転移性頭頸部扁平上皮がんで、死亡リスクを50％低減。
Genmab、ペトセムタマブ併用療法の第3相試験で全生存期間を改善──PD-L1陽性頭頸部がん一次治療、死亡リスクを50％低減
stellanews.life/technology/1...
wiseguyreports.com/reports/pd-1-and-pd-l1-monoclonal-antibodies-market www.wiseguyreports.com/reports/pd-1...
Pd 1 And Pd L1 Monoclonal Antibodies Market Size & Future Growth 2035
Pd 1 And Pd L1 Monoclonal Antibodies Market Size was estimated at 44.28 (USD Billion) in 2023. The Pd 1 And Pd L1 Monoclonal Antibodies Market Industry is expected to grow from 49.74(USD Billion) in 2...
wiseguyreports.com
October 28, 2026 at 9:07 AM
wiseguyreports.com/reports/pd-1-and-pd-l1-monoclonal-antibodies-market www.wiseguyreports.com/reports/pd-1...
Pd 1 And Pd L1 Monoclonal Antibodies Market Size & Future Growth 2035
Pd 1 And Pd L1 Monoclonal Antibodies Market Size was estimated at 44.28 (USD Billion) in 2023. The Pd 1 And Pd L1 Monoclonal Antibodies Market Industry is expected to grow from 49.74(USD Billion) in 2...
wiseguyreports.com
October 28, 2026 at 9:07 AM
US20260327307A1 Protease-cleavable VH/VL pairing constraint enables conditional antibody activation, unlike peptide-masked paratopes. MMP14 cleavage restored binding and boosted CD3×PD-L1 reporter/PBMC activation >20-fold, supporting a modular platform; in-vivo tumour selectivity remains unproven.
November 2, 2026 at 9:14 AM
US20260327307A1 Protease-cleavable VH/VL pairing constraint enables conditional antibody activation, unlike peptide-masked paratopes. MMP14 cleavage restored binding and boosted CD3×PD-L1 reporter/PBMC activation >20-fold, supporting a modular platform; in-vivo tumour selectivity remains unproven.
The authors included RRIDs in their in Nature Cancer paper! RRIDs improve reproducibility in scientific research. #STMpublishing #BetterScience #accelerateopenscience
eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer - Nature Cancer
O’Donnell and colleagues report that activation of the integrated stress response in non-small cell lung cancer cells by impairing heme production leads to enhanced PD-L1 translation in an eIF5B-dependent manner.
doi.org
October 30, 2026 at 7:01 AM
The authors included RRIDs in their in Nature Cancer paper! RRIDs improve reproducibility in scientific research. #STMpublishing #BetterScience #accelerateopenscience